

# External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation



Ernest Spitzer<sup>1</sup>, MD; Susanne Hadorn<sup>1</sup>, MD; Thomas Zanchin<sup>1</sup>, MD; Kyohei Yamaji<sup>1</sup>, MD, PhD; Aris Moschovitis<sup>1</sup>, MD; Thomas Pilgrim<sup>1</sup>, MD; Stefan Stortecky<sup>1</sup>, MD; Peter Jüni<sup>2</sup>, MD; Dik Heg<sup>3</sup>, PhD; Stephan Windecker<sup>1</sup>, MD; Lorenz Räber<sup>1\*</sup>, MD, PhD

1. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 2. Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; 3. Institute of Social and Preventive Medicine and Clinical Trials Unit, University of Bern, Bern, Switzerland

## KEYWORDS

- clinical research
- clinical trial
- death
- drug-eluting stent
- STEMI

## Abstract

**Aims:** Randomised controlled trials (RCTs) represent the most robust source of evidence-based medicine. However, the generalisability of RCTs is limited by the inclusion of selected populations. We sought to assess the external validity of a contemporary trial including patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).

**Methods and results:** Patients presenting to Bern University Hospital during the inclusion period of the COMFORTABLE AMI trial were divided into three groups: RCT participants (41%), eligible not included (17.5%), and excluded patients (41.5%). Major adverse cardiac events (MACE) were defined as one-year death and myocardial infarction. RCT participants compared with RCT-eligible patients had comparable baseline characteristics and outcomes; however, excluded patients differed in risk and had higher rates of MACE (HR 3.63, 95% CI: 2.03-6.48,  $p < 0.001$ ), death (HR 6.23, 95% CI: 2.93-13.24,  $p < 0.001$ ) and definite/probable stent thrombosis (HR 3.63, 95% CI: 1.79-7.36,  $p < 0.001$ ). Inability to provide consent was the most frequent exclusion criterion and was independently associated with an increased risk for MACE (HR 6.85, 95% CI: 3.97-11.81,  $p < 0.001$ ).

**Conclusions:** In this single-centre investigation, results from the COMFORTABLE AMI trial appeared applicable to a broad representation of RCT-eligible patients. However, patients excluded from the trial represented a higher-risk population with impaired clinical outcomes and a lower adherence to cardiovascular medication.

\*Corresponding author: Department of Cardiology, Bern University Hospital, 3010 Bern, Switzerland.  
E-mail: [lorenz.raeber@insel.ch](mailto:lorenz.raeber@insel.ch)

## Introduction

Randomised controlled trials (RCTs) represent the most robust source of evidence-based medicine and assume the highest level of support in clinical practice guidelines<sup>1</sup>. Notwithstanding this, RCTs include selected patient populations, and it remains uncertain whether the results of these studies pertain to a broader spectrum of patients encountered in daily clinical routine<sup>2</sup>. While the assessment of specific populations under controlled conditions increases the internal validity, it may jeopardise the external validity of the established results<sup>3</sup>. All-comers trials aim to recruit a wide spectrum of patients including those at higher risk for cardiac events, which should result in higher event rates and a more rapid recruitment. However, a previous single-centre report suggested that, even with an all-comers design, only approximately half of potentially eligible patients may be enrolled<sup>2</sup>.

The COMFORTABLE AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction; NCT00962416) trial, was an all-comers RCT which included 1,161 patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI)<sup>4</sup>. The use of a biolimus-eluting stent (BES) was associated with a significant reduction of the primary endpoint at one year with a sustained effect over an additional year of follow-up<sup>5</sup>. The results of this and a second PPCI trial<sup>6</sup> were the basis for a change of the ESC guidelines for myocardial revascularisation in STEMI patients (i.e., a class IA indication for the use of newer-generation DES)<sup>1</sup>.

The aim of the present study was to assess differences in baseline and procedural characteristics and long-term clinical outcomes between patients included in the COMFORTABLE AMI trial, patients who were eligible but not included in the trial, and those excluded from trial participation due to formal exclusion criteria at the centre contributing the largest patient number.

## Methods

### STUDY DESIGN AND PATIENT POPULATIONS

Details of the design of the COMFORTABLE AMI trial have been published elsewhere<sup>7</sup>. This multicentre, assessor-blinded, superiority RCT was performed at 11 sites in Europe and Israel between September 2009 and January 2011. Patients were assigned to treatment with a BES (BioMatrix™; Biosensors Europe SA, Morges, Switzerland) or a bare metal stent (BMS) (Gazelle™; Biosensors Europe SA, Morges, Switzerland).

The Bern PCI Registry (NCT02241291) is a prospective registry which includes all consecutive patients undergoing PCI at Bern University Hospital. All cardiovascular events are adjudicated by two independent physicians. Of note, adverse event monitoring, data management and event adjudication were identical between patients included in COMFORTABLE AMI and those included in the Bern PCI Registry.

All consecutive patients fulfilling the criteria of STEMI and undergoing PPCI at Bern University Hospital within the inclusion period of COMFORTABLE AMI were included in this analysis,

and divided into three groups: a) study participants (RCT), b) eligible but not included patients (eligible), and c) excluded patients (non-eligible). The study complied with the Declaration of Helsinki and was approved by the institutional ethics committee.

### DATA MANAGEMENT

Data were stored in a dedicated database (Cardibase; Clinical Trials Unit, and Department of Cardiology, Bern University Hospital, Switzerland). Complete follow-up was available for 96% of COMFORTABLE participants, 91.5% of eligible not included and 90.1% of excluded patients. COMFORTABLE AMI events were independently adjudicated by a blinded clinical events committee (CEC).

### STUDY ENDPOINTS

Similar clinical outcome definitions were applied for COMFORTABLE AMI patients and the Bern PCI Registry. The primary endpoint was the composite of all-cause death and any myocardial infarction at one year. Myocardial infarction was defined according to the extended historical definition<sup>8</sup>. Other endpoints followed the definitions of the Academic Research Consortium<sup>9</sup>.

### STATISTICAL ANALYSIS

For the purposes of the present study, data from all patients undergoing PPCI for STEMI treated in our institution during the time period of the COMFORTABLE AMI trial were analysed. Continuous variables are expressed as means±standard deviation or medians with interquartile ranges. P-values were derived using t-tests in the former and Mann-Whitney U tests in the latter. Categorical data are expressed as frequencies and percentages and are compared using the  $\chi^2$  and Fisher's exact tests. For nested variables in lesion-level data, p-values from general and generalised mixed models were used. Life-table estimates for events were calculated per group, and we used Cox regressions for comparisons. We report hazard ratios (HR) with 95% confidence intervals. In case of zero events, we reported continuity corrected risk ratios (RR) with 95% confidence intervals and Fisher's test p-values. Logistic regression was used for the identification of risk factors. All p-values shown are from two-sided tests, and the level of statistical significance was set at 0.05. Analyses were performed using Stata 12 (StataCorp LP, College Station, TX, USA).

## Results

During the time period for inclusion of the COMFORTABLE AMI trial, 608 patients underwent PPCI for STEMI at Bern University Hospital. One patient declined participation in the registry. Out of 607 patients, 252 (41.5%) did not meet eligibility criteria for the trial; 106 (17.5%) were eligible not included patients; 249 (41%) were included in the trial.

### BASELINE CHARACTERISTICS

Baseline characteristics are summarised in **Table 1**. With the exception of fewer male patients and more patients presenting with Killip III class in the eligible compared to the RCT group,

**Table 1. Baseline characteristics.**

	RCT participants N=249	Eligible patients (EP) N=106	Non-eligible patients (NEP) N=252	p-value EP vs. RCT	p-value NEP vs. RCT
Age (years)	n=249, 60.1±12.0	n=106, 61.4±13.4	n=252, 67.6±13.7	0.36	<0.001
Male gender	n=249, 211 (84.7%)	n=106, 80 (75.5%)	n=252, 184 (73.0%)	0.05	0.001
Risk factors					
Body mass index (kg/m <sup>2</sup> )	n=242, 27.2±4.0	n=97, 27.2±4.6	n=210, 27.0±4.8	0.96	0.78
Current smoking	n=248, 124 (50.0%)	n=105, 51 (48.6%)	n=237, 78 (32.9%)	0.82	<0.001
Hyperlipidaemia	n=247, 116 (47.0%)	n=106, 47 (44.3%)	n=240, 113 (47.1%)	0.73	1.00
Hypertension	n=249, 122 (49.0%)	n=106, 60 (56.6%)	n=240, 139 (57.9%)	0.20	0.06
Diabetes mellitus	n=249, 35 (14.1%)	n=106, 16 (15.1%)	n=241, 48 (19.9%)	0.87	0.09
Cardiovascular history					
Previous MI	n=249, 10 (4.0%)	n=106, 7 (6.6%)	n=241, 42 (17.4%)	0.29	<0.001
Previous PCI	n=249, 13 (5.2%)	n=106, 10 (9.4%)	n=241, 45 (18.7%)	0.16	<0.001
Previous CABG	n=249, 6 (2.4%)	n=106, 4 (3.8%)	n=242, 12 (5.0%)	0.49	0.15
History of cerebrovascular accident (Stroke/TIA)	n=249, 2 (0.8%)	n=106, 2 (1.9%)	n=241, 8 (3.3%)	0.59	0.06
Comorbidities					
Renal failure (GFR <60 mL/min/1.73 m <sup>2</sup> )	n=242, 17 (7.0%)	n=83, 10 (12.0%)	n=192, 54 (28.1%)	0.17	<0.001
Chronic obstructive lung disease	n=249, 2 (0.8%)	n=106, 3 (2.8%)	n=241, 11 (4.6%)	0.16	0.01
History of gastrointestinal bleeding	n=249, 3 (1.2%)	n=106, 1 (0.9%)	n=241, 13 (5.4%)	1.00	0.01
History of malignancy	n=249, 8 (3.2%)	n=106, 3 (2.8%)	n=241, 20 (8.3%)	1.00	0.02
Anaemia	n=243, 36 (14.8%)	n=87, 13 (14.9%)	n=204, 50 (24.5%)	1.00	0.01
Time frames					
Symptom onset to balloon inflation (min)	n=249, 274 (178; 487)	n=79, 269 (188; 493)	n=137, 286 (181; 1,143)	0.99	0.04
Symptom onset categories (hours)	n=249	n=79	n=188	0.49	<0.001
0-6 hrs	157 (63.1%)	51 (64.6%)	73 (38.8%)	0.89	<0.001
7-12 hrs	57 (22.9%)	15 (19.0%)	23 (12.2%)	0.53	0.01
13-24 hrs	31 (12.4%)	13 (16.5%)	16 (8.5%)	0.35	0.21
>24 hrs	4 (1.6%)	0 (0.0%)	76 (40.4%)	0.58	<0.001
Hospital admission to balloon inflation (min)	n=249, 40 (31; 59)	n=78, 40 (30; 91)	n=172, 67 (37; 118)	0.25	<0.001
Treatment during off-hours <sup>a</sup>	n=249, 107 (43.0%)	n=91, 49 (53.8%)	n=198, 99 (50.0%)	0.09	0.15
Killip class	n=249	n=105	n=252	0.002	<0.001
I	214 (85.9%)	82 (78.1%)	157 (62.3%)	0.08	<0.001
II	27 (10.8%)	15 (14.3%)	35 (13.9%)	0.37	0.34
III	1 (0.4%)	7 (6.7%)	14 (5.6%)	0.001	0.001
IV	7 (2.8%)	1 (1.0%)	46 (18.3%)	0.45	<0.001

Data are expressed as counts (%), *p*-values from Fisher's tests or  $\chi^2$  tests) or means±SD (*p*-values from *t*-tests) or medians (25%-75% interquartile range, *p*-values from Mann-Whitney U tests). GFR: estimated glomerular filtration rate using Modification of Diet in Renal Disease (MDRD) formula. Anaemia is defined as men <130 Hb g/L, women <120 Hb g/L. <sup>a</sup>Defined as guiding catheter inserted between 8 pm and 8 am, and at weekends.

no differences in baseline characteristics were noted. Compared with RCT participants, non-eligible patients were older, more frequently had a history of previous MI, PCI, gastrointestinal bleeding, previous malignancy, and more often suffered from chronic obstructive lung disease and anaemia.

### PROCEDURAL CHARACTERISTICS

Procedural characteristics are summarised in **Table 2**. We observed a gradient in the number of lesions treated per patient, with the

highest number of lesions treated in the non-eligible group. The need for haemodynamic support was not different between RCT participants and eligible patients, but was more frequent in the non-eligible patients; similarly, a lower LVEF was recorded in the non-eligible group.

### CARDIOVASCULAR MEDICATIONS

Medication use is summarised in **Table 3**. We observed differences in antiplatelet agents used for loading, with more frequent

**Table 2. Angiographic and procedural characteristics.**


	RCT participants N=249	Eligible patients (EP) N=106	Non-eligible patients (NEP) N=252	p-value EP vs. RCT	p-value NEP vs. RCT
Infarct-related artery					
Left anterior descending artery	108 (43.4%)	43 (40.6%)	117 (46.4%)	0.64	0.53
Lesions per patient	n=249, 1.4±0.7	n=106, 1.6±0.8	n=252, 1.8±1.1	0.02	<0.001
Multivessel treatment	n=249, 36 (14.5%)	n=106, 13 (12.3%)	n=252, 57 (22.6%)	0.74	0.02
Haemodynamic support					
IABP	n=249, 8 (3.2%)	n=106, 0 (0.0%)	n=252, 21 (8.3%)	0.11	0.02
Percutaneous left ventricular assist device	n=249, 0 (0.0%)	n=83, 0 (0.0%)	n=194, 5 (2.6%)		0.02
Vasopressors	n=249, 8 (3.2%)	n=106, 4 (3.8%)	n=252, 44 (17.5%)	0.76	<0.001
Left ventricular function	n=246, 47.2±10.2	n=101, 47.5±11.2	n=239, 42.3±11.9	0.86	<0.001
No. of treated lesions	N=343	N=167	N=446		
Lesion type					
Restenosis	n=343, 2 (0.6%)	n=167, 1 (0.6%)	n=446, 36 (8.1%)	0.98	0.001
Baseline TIMI flow	n=342	n=160	n=435	0.02	0.20
0 or 1	188 (55.0%)	76 (47.5%)	209 (48.0%)		
2	50 (14.6%)	40 (25.0%)	88 (20.2%)		
3	104 (30.4%)	44 (27.5%)	138 (31.7%)		
Thrombus aspiration	n=150, 122 (81.3%)	n=53, 29 (54.7%)	n=115, 68 (59.1%)	0.05	0.02
TIMI flow after procedure	n=343	n=161	n=439	0.51	0.25
0 or 1	3 (0.9%)	2 (1.2%)	11 (2.5%)		
2	18 (5.2%)	4 (2.5%)	27 (6.2%)		
3	322 (93.9%)	155 (96.3%)	401 (91.3%)		
Stent type					
Any newer-generation DES	n=332, 174 (52.4%)	n=146, 130 (89.0%)	n=378, 276 (73.0%)	<0.001	<0.001
Total stent length (mm)	n=332, 23.98±12.51	n=146, 25.66±13.90	n=377, 23.59±11.98	0.22	0.77
Mean stent diameter (mm)	n=332, 3.11±0.46	n=146, 2.99±0.46	n=377, 2.98±0.51	0.03	0.002

Data are expressed as counts (%) or means±SD. P-values from Fisher's tests and t-tests, respectively, for the patient-level data (upper part of the Table). P-values from general and generalised mixed models accounting for lesions nested within patients for the lesion-level data (lower part of the Table).

use of clopidogrel alone in eligible and non-eligible, and of clopidogrel and subsequent prasugrel loading in RCT participants<sup>10</sup>. In a dedicated analysis for DAPT adherence at one year (**Figure 1**), excluding patients with reasons which were expected to interfere (e.g., use of coumadin), we observed a remaining risk increase for DAPT cessation in patients not enrolled in the study.

**IN-HOSPITAL AND ONE-YEAR OUTCOMES**

We observed no differences between RCT participants and eligible patients for any cardiovascular endpoints at both time points (**Table 4**). At discharge, non-eligible patients were associated with a higher risk of MACE compared with RCT participants (HR 2.63, 95% CI: 1.57-4.41, p<0.001), which was mainly driven by differences in the rate of all-cause death (HR 2.98, 95% CI: 1.65-5.38, p<0.001) (**Figure 2A**). Results at one year were consistent (HR 3.63, 95% CI: 2.03-6.48, p<0.001), driven by the higher risk of all-cause death (HR 6.23, 95% CI: 2.93-13.24, p<0.001). A landmark analysis at 30 days revealed no interaction by time (**Figure 2B**). Non-eligible patients were not associated with an increased risk of bleeding as assessed using the BARC, TIMI and GUSTO classifications.



**Figure 1. Dual antiplatelet therapy (DAPT) cessation within one year. First stop recorded as time-to-DAPT cessation. Patients meeting the following criteria were excluded from this analysis: in-hospital death (31), without DAPT at discharge (19), lost at follow-up (45), oral anticoagulation at discharge (13), history of bleeding diathesis (7), and planned surgery with DAPT interruption (11). Blue: study participants (SP); green: eligible not included patients (EP); red: non-eligible patients (NEP); USD: number of patients with uncertain stop dates.**

**Table 3. Medication use during the index procedure, at discharge and at one-year follow-up.**

	RCT participants N=249	Eligible patients (EP) N=106	Non-eligible patients (NEP) N=252	p-value EP vs. RCT	p-value NEP vs. RCT
<b>During index PCI</b>					
P2Y <sub>12</sub> inhibitors	n=249	n=106	n=252	<0.001	<0.001
Only clopidogrel loading	35 (14.1%)	46 (43.4%)	154 (61.1%)	<0.001	<0.001
Only prasugrel loading	35 (14.1%)	12 (11.3%)	33 (13.1%)	0.61	0.80
Clopidogrel and prasugrel loading	179 (71.9%)	44 (41.5%)	47 (18.7%)	<0.001	<0.001
<b>At discharge</b>					
Aspirin, n (%)	n=245, 245 (100.0%)	n=105, 105 (100.0%)	n=228, 217 (95.2%)		<0.001
Clopidogrel, n (%)	n=245, 27 (11.0%)	n=105, 40 (38.1%)	n=228, 130 (57.0%)	<0.001	<0.001
Prasugrel, n (%)	n=245, 218 (89.0%)	n=105, 64 (61.0%)	n=228, 87 (38.2%)	<0.001	<0.001
Any DAPT, n (%)	n=245, 245 (100.0%)	n=105, 104 (99.0%)	n=228, 208 (91.2%)	0.30	<0.001
Oral anticoagulation, n (%)	n=245, 1 (0.4%)	n=104, 0 (0.0%)	n=228, 16 (7.0%)	1.00	<0.001
Statin, n (%)	n=245, 244 (99.6%)	n=104, 101 (97.1%)	n=228, 212 (93.0%)	0.08	<0.001
<b>At one year</b>					
Aspirin, n (%)	n=231, 229 (99.1%)	n=90, 88 (97.8%)	n=175, 163 (93.1%)	0.31	0.001
Clopidogrel, n (%)	n=231, 26 (11.3%)	n=91, 32 (35.2%)	n=175, 86 (49.1%)	<0.001	<0.001
Prasugrel, n (%)	n=231, 192 (83.1%)	n=90, 48 (53.3%)	n=175, 37 (21.1%)	<0.001	<0.001
Any DAPT, n (%)	n=231, 216 (93.5%)	n=90, 77 (85.6%)	n=175, 115 (65.7%)	0.03	<0.001
Oral anticoagulation, n (%)	n=229, 9 (3.9%)	n=90, 1 (1.1%)	n=174, 15 (8.6%)	0.29	0.06
Statin, n (%)	n=229, 221 (96.5%)	n=90, 83 (92.2%)	n=173, 159 (91.9%)	0.14	0.05

Data are expressed as counts (%), p-values from Fisher's tests). Loading includes patients who were already on a daily dosage of the indicated APT.


**PREDICTORS OF EVENTS AMONG RCT NON-ELIGIBLE PATIENTS**

Exclusion criteria that were independently associated with a significantly higher rate of MACE were inability to provide informed consent (HR 6.85, 95% CI: 3.97-11.81,  $p<0.001$ ), increased baseline bleeding risk (HR 3.59, 95% CI: 1.66-7.77,  $p=0.001$ ), and mechanical complications of acute MI (HR 8.73, 95% CI: 2.05-37.07,  $p=0.003$ ) (Figure 3).


**Discussion**

The principal findings of this single-centre investigation of the external validity of a contemporaneous PPCI trial are as follows:

1. In-hospital and one-year cardiovascular event rates were comparable between STEMI patients enrolled in the COMFORTABLE AMI trial and RCT-eligible but not included patients, attesting to the external validity of the results of the original trial.



**Figure 2. Kaplan-Meier curves and landmark analysis. A) All-cause death or myocardial infarction at one year. B) Landmark analysis at 30 days and between 30 days and one year for all-cause death or myocardial infarction. Blue: study participants, green: eligible not included patients, red: non-eligible patients.**



**Figure 3.** Effect of individual exclusion criteria on all-cause death and myocardial infarction at one year. <sup>a</sup>Events in RCT participants and RCT-eligible patients. <sup>b</sup>Continuity corrected risk ratio (95% CI) with Fisher's exact test.

- Baseline characteristics were comparable among RCT participants and RCT-eligible patients, whereas RCT-ineligible patients carried a higher burden of comorbidities and procedural factors.
- STEMI patients fulfilling exclusion criteria carried a higher cardiovascular mortality, without difference in the risk of myocardial infarction or repeat revascularisation.
- RCT participants underwent more structured invasive and pharmacological interventions and showed an increased adherence to recommended cardiovascular medication including DAPT when compared with non-trial participants.
- Inability to provide informed consent was the most frequent exclusion criterion and was associated with a seven times higher risk of death or myocardial infarction.

External validity is defined as the reasonable applicability of the results of a study to a definable group of patients in a particular clinical setting in routine clinical practice<sup>3</sup>. Rothwell et al proposed six criteria for the assessment of external validity<sup>3</sup>. We previously reported details on the selection of patients, outcome measures, follow-up quality and adverse effects of the treatment<sup>4</sup>. The present analysis focuses on the characteristics of randomised versus non-randomised patients and differences between the trial protocol and routine clinical practice at the centre contributing the largest patient number of the trial.

All patients included in this analysis were screened by a dedicated physician (24 hours/7 days) for enrolment into the PPCI trial. Pre-specified exclusion criteria were met by 41% of patients

**Table 4. Clinical outcomes at discharge and at one-year follow-up.**

	RCT participants N= 49	Eligible patients (EP) N=106	Non-eligible patients (NEP) N=252	EP vs. RCT		NEP vs. RCT		
				HR or RR (95% CI)	p-value	HR or RR (95% CI)	p-value	
Death or MI (any)	15 (6.1)	8 (7.9)	48 (20.2)	1.31 (0.55-3.09)	0.54	3.63 (2.03-6.48)	<0.001	
Cardiac death, TV-MI, TLR (DOCE)	18 (7.3)	7 (7.0)	45 (19.1)	0.95 (0.40-2.28)	0.92	2.84 (1.65-4.91)	<0.001	
Death, MI, any revasc (POCE)	22 (9.0)	13 (13.0)	59 (25.0)	1.47 (0.74-2.92)	0.27	3.11 (1.90-5.07)	<0.001	
Death	8 (3.2)	5 (5.0)	44 (18.5)	1.52 (0.50-4.64)	0.46	6.23 (2.93-13.24)	<0.001	
Cardiac death	8 (3.2)	4 (4.0)	38 (15.9)	1.21 (0.36-4.02)	0.76	5.31 (2.48-11.39)	<0.001	
Myocardial infarction	8 (3.3)	4 (4.0)	4 (2.0)	1.24 (0.37-4.13)	0.72	0.59 (0.18-1.96)	0.39	
Revascularisation (any)	17 (7.1)	9 (9.2)	15 (7.7)	1.35 (0.60-3.02)	0.47	1.07 (0.53-2.14)	0.85	
Revascularisation (TLR)	13 (5.4)	4 (4.0)	7 (3.7)	0.77 (0.25-2.37)	0.65	0.65 (0.26-1.62)	0.35	
Revascularisation (TVR)	13 (5.4)	5 (5.1)	9 (4.7)	0.96 (0.34-2.71)	0.95	0.84 (0.36-1.96)	0.68	
Stent thrombosis (definite)	5 (2.0)	3 (3.0)	2 (0.9)	1.47 (0.35-6.15)	0.60	0.47 (0.09-2.40)	0.36	
BARC bleeding	Bleeding BARC (3abc)	9 (3.7)	1 (0.9)	7 (3.2)	0.27 (0.03-2.10)	0.21	0.85 (0.32-2.28)	0.74
	Bleeding BARC (4)	0 (0.0)	0 (0.0)	0 (0.0)				
	Bleeding BARC (5ab)	1 (0.4)	0 (0.0)	2 (0.9)	0.78 (0.03-18.99)	100	2.16 (0.20-23.84)	0.53

Depicted are number of first events (% from life-table estimates) per group, and the results of Cox regressions comparing the eligible not included patients vs. study participants, and the not eligible patients vs. study participants, hazard ratios (HR) with 95% confidence intervals, and p-values. Continuity corrected risk ratios (RR) with 95% confidence intervals, and Fisher's test p-values reported in case of zero events.

and an additional 18% either declined participation or were not included, as factors were present that precluded randomisation despite not being predefined as exclusion criteria. In addition, factors unrelated to the patients may have prevented timely consent and randomisation, such as treatment of multiple STEMI patients at the same time, unavailability of both stents, or fatigue of the operator during night hours. Overall, two thirds of eligible patients were actually included in the RCT. A comparable inclusion rate (60%) was reported in the Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial, a contemporaneous all-comers RCT in STEMI patients investigating the impact of thrombus aspiration on mortality at 30 days<sup>11</sup>. Conversely, the recently published How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) trial was able to randomise 95% of patients scheduled for an emergent angiography<sup>12</sup>. The high inclusion rate was largely the consequence of a policy of delayed consent, preserving the inclusion of critically ill patients who were unable to provide consent before the procedure.

Patients who were not eligible for RCT inclusion showed a significantly higher baseline risk profile in this analysis. It is noteworthy that one third was unable to provide informed consent owing to a critical condition including a sixfold more frequent presentation with Killip class IV compared with trial participants, which in turn is one of the strongest predictors of mortality among STEMI patients<sup>13</sup>. As a result, the present study indicates that in-hospital and one-year outcomes are considerably impaired among RCT-ineligible patients. Similar findings have been reported in a recent sub-analysis of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial<sup>14</sup>. Exclusion due to late presentation (>24 hours) was not infrequent. Although PPCI may be considered for this subset of patients, several factors (i.e., residual ischaemia, intermittent coronary flow, or collateral flow) may influence the benefits expected from the intervention, preventing to some degree the comparability with patients receiving early invasive treatment<sup>15</sup>.

Eligible not included patients have shown a higher baseline risk when compared to included patients in previous studies, denoting the impact of clinical selection beyond eligibility criteria<sup>16</sup>. We identified conditions that may have influenced the decision to enrol the patient such as multiple comorbidities, doubtful future adherence (i.e., drug addiction, psychiatric disorders), among others, in the eligible not included group. Both the beneficial impact of experimental interventions or therapies and a closer medical attention have been suggested as reasons for improved outcomes in RCT participants<sup>16,17</sup>. Indeed, a more aggressive antiplatelet treatment was observed in RCT participants (i.e., more frequent use of glycoprotein IIb/IIIa inhibitors and prasugrel), as well as a higher frequency of patients on DAPT throughout one year. Specifically, we observed that real-life STEMI patients tend to stop DAPT earlier than initially prescribed, a finding suggesting that adherence to DAPT requires monitoring by the treating GP or cardiologist.

Despite these differences, a similar baseline risk and comparable cardiovascular event rates were observed in this all-comers RCT among RCT participants and eligible not included patients, attesting to the high degree of external validity. Considering the impact of COMFORTABLE AMI (together with EXAMINATION) on the current revascularisation guidelines, fulfilling the requirements for external validity is of great importance. In agreement with our data, the TWENTE all-comers trial confirmed similar clinical outcomes in study patients and eligible not included NSTEMI patients<sup>17</sup>.

While there is no evidence against the applicability of the results in non-eligible patients, or a pathophysiological basis to support such conclusions<sup>18</sup>, it seems prudent to rely on RCTs and clinical guidelines for decision making. Notwithstanding this, the increasing complexity of patients undergoing interventional procedures today often compels us to an individualised approach. The effect of drugs and devices may differ in subsets of patients largely excluded from RCTs. To improve the representation of critically ill patients within RCTs, postponing the informed consent to a time point after the random treatment allocation may be the only solution, something that certainly requires intense ethical consideration.

## Limitations

Our results have to be interpreted in view of the following limitations. First, despite the multicentre nature of the COMFORTABLE AMI trial, we performed our analysis based on data from a single centre that contributed the largest number of patients. The availability of a prospective registry and the unified criteria for definition of events at Bern University Hospital have favoured this approach, and this strategy has been utilised in previous studies<sup>2,14</sup>. Second, reasons for eligibility beyond exclusion criteria were not prospectively recorded, and we were not able to provide the reasons that prevented randomisation for the majority of eligible, non-randomised patients. Third, the use of drug-eluting stents was underrepresented in the RCT population; however, limitations inherent to the sample size prevented stratification by stent type for the purpose of comparisons. Fourth, longer follow-up may identify differences that cannot be detected in a one-year period. However, Kaplan-Meier curves suggest that the findings of the current analysis may prevail over time. Finally, as a *post hoc* analysis, the present study should be considered exploratory and hypothesis-generating.

## Conclusions

Contemporaneous RCTs in patients presenting with ST-elevation myocardial infarction, with less stringent exclusion criteria, provide an appropriate representation of eligible not included patients if conducted using an all-comers approach. Excluded patients represent a higher-risk population, and caution should be applied when extrapolating results from RCTs to this subset of patients. Inability to provide written consent is the most frequent reason for exclusion and associated with a substantially increased mortality.

## Impact on daily practice

Results from the COMFORTABLE AMI trial in patients undergoing primary percutaneous coronary intervention for STEMI may be generalised to populations fulfilling trial-specific eligibility criteria. However, patients excluded exhibited worse baseline conditions, higher event rates, and lower adherence to cardiovascular medications. Admission in a critical condition, not allowing the patient to provide informed consent for a randomised trial, and an increased bleeding risk were independently associated with a higher risk of clinical events at one year, denoting the importance of close monitoring for these patients.

## Funding

S. Windecker and P. Jüni were supported by the Swiss National Science Foundation (33CM30-124112 and 310030-118353). E. Spitzer received a Research Fellowship from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology and a research grant from the Spanish Society of Cardiology. Thomas Zanchin is supported by the Swiss National Science Foundation (323530-171146). The COMFORTABLE trial was supported by an unrestricted research grant from Biosensors Europe SA, Switzerland.

## Conflict of interest statement

Clinical Trials Unit Bern, which is part of the University of Bern, has a staff policy of not accepting honoraria or consultancy fees. S. Windecker has received research contracts to the institution from Abbott, Boston Scientific, Biosensors, Biotronik, Cordis, and Medtronic. P. Jüni is an unpaid steering committee or statistical executive committee member of trials funded by Abbott Vascular, Biosensors, Medtronic, and St. Jude Medical. L. Räber has received research contracts to the institution from St. Jude Medical. The other authors have no conflicts of interest to declare.

## References

1. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*. 2014;35:2541-619.
2. de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. *Eur Heart J*. 2011;32:2161-7.

3. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". *Lancet*. 2005;365:82-93.
4. Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Lüscher TF, Taniwaki M, Matter CM, Meier B, Jüni P, Windecker S; COMFORTABLE AMI Trial Investigators. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. *JAMA*. 2012;308:777-87.
5. Räber L, Kelbæk H, Taniwaki M, Ostojic M, Heg D, Baumbach A, von Birgelen C, Roffi M, Tüller D, Engstrøm T, Moschovitis A, Pedrazzini G, Wenaweser P, Kornowski R, Weber K, Lüscher TF, Matter CM, Meier B, Jüni P, Windecker S; COMFORTABLE AMI Trial Investigators. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. *Circ Cardiovasc Interv*. 2014;7:355-64.
6. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martín-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. *Lancet*. 2012;380:1482-90.
7. Räber L, Kelbæk H, Ostojic M, Baumbach A, Tüller D, von Birgelen C, Roffi M, Pedrazzini G, Kornowski R, Weber K, Heg D, Matter C, Lüscher T, Taniwaki M, Meier B, Jüni P, Windecker S. Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. *EuroIntervention*. 2012;7:1435-43.
8. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. *EuroIntervention*. 2010;5:871-4.
9. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation*. 2007;115:2344-51.
10. Räber L, Klingenberg R, Heg D, Kelbæk H, Roffi M, Tüller D, Baumbach A, Zanchin T, Carballo D, Ostojic M, Stefanini GG, Rodondi N, von Birgelen C, Moschovitis A, Engstrøm T, Gencer B, Auer R, Meier B, Mach F, Lüscher TF, Jüni P, Matter CM, Windecker S; COMFORTABLE and SPUM-ACS Trial Investigators. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. *JACC Cardiovasc Interv*. 2015;8:1064-74.

11. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angerås O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johansson AC, Kåregren A, Nilsson J, Robertson L, Sandhall L, Sjögren I, Ostlund O, Harnek J, James SK; TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med*. 2013;369:1587-97.
12. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH; HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. *Lancet*. 2014;384:1849-58.
13. Taniwaki M, Stefanini GG, Räber L, Brugaletta S, Cequier A, Heg D, Iñiguez A, Kelbæk H, Serra A, Ostojic M, Hernandez-Antolin R, Baumbach A, Blöchlinger S, Jüni P, Mainar V, Sabate M, Windecker S. Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials. *EuroIntervention*. 2015;11:391-8.
14. Fiocca L, Guagliumi G, Rossini R, Parise H, Musumeci G, Sirbu V, Lortkipanidze N, Yu J, Mihalesik L, Vassileva A, Valsecchi O, Gavazzi A, Mehran R, Stone GW. Characteristics and outcomes of patients with ST-segment elevation myocardial infarction excluded from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial. *Am J Cardiol*. 2013;111:196-201.
15. Cohen M, Boiangiu C, Abidi M. Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. *J Am Coll Cardiol*. 2010;55:1895-906.
16. Steg PG, López-Sendón J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F; GRACE Investigators. External validity of clinical trials in acute myocardial infarction. *Arch Intern Med*. 2007;167:68-73.
17. Sen H, Tandjung K, Basalus MW, Löwik MM, van Houwelingen GK, Stoel MG, Louwerenburg HW, de Man FH, Linssen GC, Nijhuis R, Nienhuis MB, Verhorst PM, van der Palen J, von Birgelen C. Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents. *EuroIntervention*. 2012;8:664-71.
18. Horton R. Common sense and figures: the rhetoric of validity in medicine (Bradford Hill Memorial Lecture 1999). *Stat Med*. 2000;19:3149-64.